Single-dose liposomal amphotericin B (AmBisome®) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial

Tansy Edwards, Raymond Omollo, Eltahir A G Khalil, Sisay Yifru, Brima Musa, Ahmed Musa, Monique Wasunna, Peter G Smith, Catherine Royce, Sally Ellis, Manica Balasegaram, Asrat Hailu, Tansy Edwards, Raymond Omollo, Eltahir A G Khalil, Sisay Yifru, Brima Musa, Ahmed Musa, Monique Wasunna, Peter G Smith, Catherine Royce, Sally Ellis, Manica Balasegaram, Asrat Hailu

Abstract

Background: AmBisome® is an efficacious, safe anti-leishmanial treatment. There is growing interest in its use, either as a single dose or in combination treatments. In East Africa, the minimum optimal single-dosage has not been identified.

Methods/design: An open-label, 2-arm, non-inferiority, multi-centre randomised controlled trial is being conducted to determine the optimal single-dose treatment with AmBisome®.Patients in the single-dose arm will receive one infusion on day 1, at a dose depending on body weight. For the first group of patients entered to the trial, the dose will be 7.5 mg/kg, but if this dose is found to be ineffective then in subsequent patient series the dose will be escalated progressively to 10, 12.5 and 15 mg/kg. Patients in the reference arm will receive a multi-dose regimen of AmBisome® (3 mg/kg/day on days 1-5, 14 and 21: total dose 21 mg/kg). Patients will be hospitalised for approximately one month after the start of treatment and then followed up at three and six months. The primary endpoint is the status of patients six months after treatment. A secondary endpoint is assessment at day 30. Treatment success is determined as the absence of parasites on microscopy samples taken from bone marrow, lymph node or splenic aspirates. Interim analyses to assess the comparative efficacy of the single dose are planned after recruitment of 20 and 40 patients per arm. The final non-inferiority analysis will include 120 patients per arm, to determine if the single-dose efficacy 6 months after treatment is not more than 10% inferior to the multi-dose.

Discussion: An effective, safe single-dose treatment would reduce hospitalization and treatment costs. Results will inform the design of combination treatment studies.

Trial registration: ClinicalTrials.gov NCT00832208.

Figures

Figure 1
Figure 1
Trial Flow CONSORT Diagram. 1 dosage: 3 mg/kg on days 1-5, 7 and 14 (total dose 21 mg/kg). 2 possible single-doses of 7.5, 10, 12.5 & 15 mg/kg on day 1.

References

    1. Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol. 1996;14:417–423. doi: 10.1016/0738-081X(96)00057-0.
    1. van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M. Combination therapy for visceral leishmaniasis. Lancet Infect Dis. 2010;10:184–194. doi: 10.1016/S1473-3099(10)70011-6.
    1. Seaman J, Mercer AJ, Sondorp E. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol. 1996;25:862–871. doi: 10.1093/ije/25.4.862.
    1. Zijlstra EE, el-Hassan AM. Leishmaniasis in Sudan. Visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2001;95(Suppl 1):S27–58. doi: 10.1016/S0035-9203(01)90218-4.
    1. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ. 2001;323:419–422. doi: 10.1136/bmj.323.7310.419.
    1. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010;362:504–512. doi: 10.1056/NEJMoa0903627.
    1. Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis. 2008;47:1000–1006. doi: 10.1086/591972.
    1. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ. 1998;76:25–32.
    1. Gilead Sciences Ltd. AmBisome: Summary of Product Characteristics. Granta Park, Abington, Cambridge, CB21 6GT, UK; 2008.
    1. Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S. et al.Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis. 2010;4:e709. doi: 10.1371/journal.pntd.0000709.
    1. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ. 1996;313:36–39.
    1. Kirkwood B, Sterne J. Essential Medical Statistics. Second. Blackwell Science Ltd; 2003.
    1. Ryan P. sxd1. Random allocation of treatments in blocks. Stata Technical Bulletin. 1998;STB-41:43–46.
    1. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K. et al.Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006;43:917–924. doi: 10.1086/507530.
    1. Thakur CP. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents. 2001;17:67–70. doi: 10.1016/S0924-8579(00)00312-5.
    1. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis. 2003;37:800–804. doi: 10.1086/377542.
    1. Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis. 2007;45:556–561. doi: 10.1086/520665.
    1. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events Version 3.0 DCTD, NCI, NIH, DHHS. Publish Date: August 9 2006.
    1. TDR Special Programme for Research and Training in Tropical Diseases 2005: Operational Guidelines for the Establishment and Functioning of Data and Safety Monitoring Boards.
    1. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
    1. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects.
    1. Akaza Research Massachusetts USA. 2003.
    1. StataCorp LP College Station Texas 77845 USA. 1996.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe